Products
Briquilimab Biosimilar Monoclonal Antibody (c-Kit) for Research
Cat No.: GMP-Bios-INN-1111
Anti-KIT/CD117 therapeutic antibody (Pre-made Briquilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Briquilimab (development codes JSP-191/AMG 191) is a humanized monoclonal antibody targeting KIT (CD117). It is developed by Jasper Therapeutics as an antibody-based conditioning regimen for hematopoietic stem cell transplantation. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1111-1mg | 1mg | 3090 |
| GMP-Bios-INN-1111-10mg | 10mg | |
| GMP-Bios-INN-1111-100mg | 100mg | |
| GMP-Bios-INN-1111-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Briquilimab biosimilar, Whole mAb, Anti-KIT/CD117 Antibody: Anti-CD117/c-Kit/KIT/Mast therapeutic antibody |
| INN Name | Briquilimab |
| Target | KIT/CD117 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Jasper Therapeutics;Amgen;National Heart;Lung and Blood Institute;Stanford University |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Inflammation;Acute myeloid leukemia;Severe combined immunodeficiency |
| Production | na |
| Development Tech | na |
